Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as Titf1/Nkx2-1 and Pax-8 transcription factor genes in papillary thyroid cancer

Thyroid

Volumn 15, Issue 10, 2005, Pages 1137-1146

  Ambroziak, Michal ^a   Pachucki, Janusz ^b   Stachlewska Nasfeter, Elzbieta ^c   Nauman, Janusz ^d   Nauman, Alicja ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; MESSENGER RNA; PROPYLTHIOURACIL; THYROXINE; THYROXINE DEIODINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2 1; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR TITF1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROSOME; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ISOLATION; STATISTICAL ANALYSIS; THYROID HORMONE SYNTHESIS; THYROID PAPILLARY CARCINOMA; TUMOR BIOPSY;

ADULT; CARCINOMA, PAPILLARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODIDE PEROXIDASE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PAIRED BOX TRANSCRIPTION FACTORS; RNA, MESSENGER; THYROID GLAND; THYROID NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 28344442294     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.1137     Document Type: Article

References (40)

1. Lauberg P 1984 Mechanisms governing the relative proportions of thyroxine and 3,5,3′-triiodothyronine in thyroid secretion. Metabolism 33:379-392.
2. Izumi M, Larsen PR 1977 Triiodothyronine, thyroxine, and iodine in purified thyroglobulin from patients with Graves' disease. J Clin Invest 59:1105-1112.
3. Larsen PR 1975 Thyroidal triiodothyronine and thyroxine in Graves' disease: Correlation with presurgical treatment, thyroid status, and iodine content. J Clin Endocrinol Metab 41:1098-1104.
4. Berry MJ, Kieffer JD, Harney JW, Larsen PR 1991 Selenocysteine confers the biochemical properties of the type I iodothyronine deiodinase. J Biol Chem 266:14155-14158.
5. Buettner C, Harney JW, Larsen PR 2000 The role of selenocysteine of 133 in catalysis by the human type 2 iodothyronine deiodinase. Endocrinology 141:4606-4612.
6. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89.
7. Salvatore D, Tu H, Harney JW, Larsen PR 1996 Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest 98:962-968.
8. Berry MJ, Banu L, Larsen PR 1991 Type I iodothyronine deiodinase is a selenocysteine-containing enzyme. Nature 349:438-440
9. Zhang C, Kim S, Harney JW, Larsen PR 1998 Further characterization of thyroid hormone response elements in the human type 1 iodothyronine deiodinase gene. Endocrinology 139:1156-1163.
10. Toyoda N, Nisihikawa M., Horimoto M., Yoshikawa N, Mori Y, Yoshimura M., Masaki H, Tanaka K, Inada M 1990 Synergistic effect of thyroid hormone and thyrotropin on iodothyronine 5′-deiodinase in FRTL-5 rat thyroid cells. Endocrinology 127:1199-1205.
11. Friedrichsen S, Christ S, Heuer H, Schafer MK, Mansouri A, Bauer A, Visser TJ 2003 Regulation of iodothyronine deiodinases in the Pax-8-/- mouse model of congenital hypothyroidism. Endocrinology 144:777-784.
12. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P, Larsen PR 2000 Characterization of the 5-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′-monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology 141:229-237.
13. Gereben B, Salvatore D, Harney JW, Tu HM, Larsen PR 2001 The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1). Mol. Endocrinol 15:112-124.
14. Burmeister LA, Pachucki J, St. Germain DL 1997 Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. Endocrinology 138:5231-5237.
15. St. Germain DL 1988 The effects and interactions of substrates, inhibitors, and the cellular thiol-disulfide balance on the regulation of type II iodothyronine 5′-deiodinase. Endocrinology 122:1860-1868.
16. Murakami M, Ataki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, Mizuma H, Mori M 2001 Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 142:2961-2967.
17. De Felice M, Di Lauro R. 2004 Thyroid development and its disorders: Genetics and molecular mechanisms. Endocr Rev 25:722-746.
18. Miccadei S, De Leo R, Zammarchi E, Natali PG, Civitareale D 2002 The synergistic activity of thyroid transcription factor 1 and Pax 8 relies on the promoter/enhancer interplay. Mol Endocrinol 16:837-846.
19. Ros P, Rossi DL, Acebron A, Santisteban P 1999 Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochemie 81:389-396.
20. Fabbro D, Di Loreto C, Beltrami A, Belfiore A, Di Lauro R, Damante G 1994 Expression of the thyroid-specific transcription factors TTF-1 and Pax-8 in human thyroid neoplasms. Cancer Res 54:4744-4749.
21. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72:248-254.
22. Leonard JL, Resenberg IN. 1980 Iodothyronine 5′ deiodinase from rat kidney: Substrat specifity and the 5′-deioidnation of reverse triiodothyronine. Endocrinology 107:1376-1383.
23. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
24. Ambroziak M, Pachucki J, Chojnowski K, Wiechno W, Nauman J, Nauman A 2003 Pax-8 expression correlates with type II 5′ deiodinase expression in thyroids from patients with Graves' disease. Thyroid 13:141-148.
25. Pachucki J, Ambroziak M, Tanski Z, Luczak J, Nauman J, Nauman A 2001 Type I 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest 24:253-261.
26. Di Palma T, Nitsch R, Mascia A, Nitsch L, Di Lauro R, Zannini M 2003 The paired domain-containing factor Pax-8 and the homeodomian-containing factor TTF-1 directly interact and synergistically activate transcription. J Biol Chem 278:3395-3402.
27. Katoh R, Miyagi E, Nakamura N, Li X, Suzuki K, Kakudo K, Kobayashi M, Kawaoi A 2000 Expression of thyroid transcription factor-1 (TTF-I) in human C cells and medullary thyroid carcinoma. Hum Pathol 31:386-393.
28. Mettinen M, Franssila KO 2000 Variable Expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol 31:1139-1145.
29. Katoh R, Kawaoi A, Miyagi E, Li X, Suzuki K, Nakamura Y, Kakudo K 2000 Thyroid transcription factor-1 in normal, hyperplasctic, and neoplastic follicular thyroid cells examined by immunochemistry and nonradioactive in situ hybridization. Mod. Pathol. 13:570-576.
30. Zannini M, Acebron A, De Felice M, Arnone MI, Martin-Perez J, Santisteban P 1996 Mapping and functional role of phosphorylation sites in the thyroid transcription factor 1 (TTF-1). J Biol Chem 27:2249-2254.
31. Arnone MI, Zannini M, Di Lauro R 1995 The DNA binding activity and the dimerization ability of the thyroid tran-scription factor 1 are redox regulated. J Biol Chem 270:12048-12055.
32. De Felice M, Damante G, Zannini M, Francis-Lang H, Di Lauro R 1995 Redundant domains contribute to the transcriptional activity of the thyroid transcription factor 1. J Biol Chem 270:26649-26656.
33. Shimura H, Suzuki H, Miyazaki A, Furuya F, Ohta K, Haraguchi K, Endo T, Onaya T 2001 Transcriptional activation of the thyroglobulin promoter directing sucide gene expression by thyroid transcription factor-1 in thyroid cancer cells. Cancer Res 61:3640-3646.
34. Maulbecker CC, Gruss P 1993 The oncogenic potential of Pax genes. EMBO J 12:2361-2367.
35. Mentrup B, Herbert S, Schmutzler C, Koehrle J 2002 The expression of the human type I 5′ iodothyronine deiodinase depends on the methylation status of the cell. J Endocrinol Invest 25:29.
36. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J 2002 Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87:1120-1128.
37. Singh B, Lim D, Cigudosa JC, Ghossein R, Shaha AR, Poluri A, Wreesmann VB, Tuttle M, Shah JP, Rao PH 2000 Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization. Surgery 128:889-893.
38. Jakobs TC, Koehler MR, Schmutzler C, Glaser F, Schmid M, Koehrle J 1997 Strucuture of the human type I iodothyronine 5′-deiodinase gene and localization to chromsome Ip32-p33. Genomics 42:361-363.
39. Gereben B, Kollar A, Harney JW, Larsen PR 2002 The mRNA structure has potenet regulatory effects on type 2 iodothyronine deiodinase expression. Mol Endocrinol 16:1667-1679.
40. Gereben B, Goncalves C, Harney JW, Larsen PR, Bianco AC 2000 Selective proteolysis of human type 2 deiodinase: A novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol 14:1697-1708.